Scandinavian ChemoTech AB (publ) (CMOTEC-B.ST)
SEK 1.33
(-4.68%)
SEK 1.33
(-4.68%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 14.86 Million SEK | -31.48% |
| 2022 | 21.7 Million SEK | -15.92% |
| 2021 | 25.81 Million SEK | 61.4% |
| 2020 | 15.99 Million SEK | -8.57% |
| 2019 | 17.48 Million SEK | -23.32% |
| 2018 | 22.8 Million SEK | 77.58% |
| 2017 | 12.84 Million SEK | -23.67% |
| 2016 | 16.82 Million SEK | 152.93% |
| 2015 | 6.65 Million SEK | 9995.57% |
| 2014 | 65.89 Thousand SEK | 48.4% |
| 2013 | 44.4 Thousand SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 15.22 Million SEK | -6.06% |
| 2024 Q1 | 16.21 Million SEK | 9.02% |
| 2023 Q2 | 20.49 Million SEK | 7.01% |
| 2023 FY | 14.86 Million SEK | -31.48% |
| 2023 Q4 | 14.86 Million SEK | -12.94% |
| 2023 Q1 | 19.14 Million SEK | -11.77% |
| 2023 Q3 | 17.07 Million SEK | -16.65% |
| 2022 Q1 | 20.62 Million SEK | -20.09% |
| 2022 FY | 21.7 Million SEK | -15.92% |
| 2022 Q3 | 18.64 Million SEK | -2.9% |
| 2022 Q4 | 21.7 Million SEK | 16.38% |
| 2022 Q2 | 19.2 Million SEK | -6.89% |
| 2021 Q3 | 31.19 Million SEK | 56.89% |
| 2021 FY | 25.81 Million SEK | 61.4% |
| 2021 Q2 | 19.88 Million SEK | -6.48% |
| 2021 Q4 | 25.81 Million SEK | -17.25% |
| 2021 Q1 | 21.25 Million SEK | 32.94% |
| 2020 Q3 | 19.41 Million SEK | -14.04% |
| 2020 Q1 | 16.85 Million SEK | -3.63% |
| 2020 FY | 15.99 Million SEK | -8.57% |
| 2020 Q2 | 22.59 Million SEK | 34.04% |
| 2020 Q4 | 15.99 Million SEK | -17.65% |
| 2019 Q4 | 17.48 Million SEK | -19.09% |
| 2019 FY | 17.48 Million SEK | -23.32% |
| 2019 Q3 | 21.61 Million SEK | 8.75% |
| 2019 Q2 | 19.87 Million SEK | -4.68% |
| 2019 Q1 | 20.85 Million SEK | -8.58% |
| 2018 FY | 22.8 Million SEK | 77.58% |
| 2018 Q2 | 28.43 Million SEK | 164.0% |
| 2018 Q1 | 10.77 Million SEK | 0.0% |
| 2018 Q3 | 23.38 Million SEK | -17.78% |
| 2018 Q4 | 22.8 Million SEK | -2.46% |
| 2017 Q2 | 16.82 Million SEK | -12.31% |
| 2017 FY | 12.84 Million SEK | -23.67% |
| 2017 Q1 | 19.18 Million SEK | -18.87% |
| 2017 Q3 | 14.64 Million SEK | -12.98% |
| 2016 Q4 | 23.65 Million SEK | 0.0% |
| 2016 FY | 16.82 Million SEK | 152.93% |
| 2016 Q2 | 6.65 Million SEK | 0.0% |
| 2015 FY | 6.65 Million SEK | 9995.57% |
| 2015 Q3 | - SEK | 0.0% |
| 2014 FY | 65.89 Thousand SEK | 48.4% |
| 2013 FY | 44.4 Thousand SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 99.218% |
| AcouSort AB (publ) | 34.51 Million SEK | 56.918% |
| Active Biotech AB (publ) | 44 Million SEK | 66.207% |
| Alzinova AB (publ) | 123.18 Million SEK | 87.93% |
| Amniotics AB (publ) | 26.08 Million SEK | 43.0% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -144.677% |
| BioArctic AB (publ) | 1.18 Billion SEK | 98.746% |
| Camurus AB (publ) | 1.9 Billion SEK | 99.221% |
| Cantargia AB (publ) | 223.71 Million SEK | 93.354% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | 50.721% |
| Genovis AB (publ.) | 288.85 Million SEK | 94.852% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 82.554% |
| Mendus AB (publ) | 755.95 Million SEK | 98.033% |
| Kancera AB (publ) | 65.64 Million SEK | 77.349% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 98.818% |
| LIDDS AB (publ) | 17.65 Million SEK | 15.78% |
| Lipum AB (publ) | 12.11 Million SEK | -22.783% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | 55.75% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 94.666% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | 25.807% |
| NextCell Pharma AB | 81.28 Million SEK | 81.708% |
| OncoZenge AB (publ) | 20.34 Million SEK | 26.898% |
| Saniona AB (publ) | 64.14 Million SEK | 76.819% |
| Simris Alg AB (publ) | 174.55 Million SEK | 91.482% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 97.004% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 97.725% |
| Xintela AB (publ) | 18.39 Million SEK | 19.168% |
| Ziccum AB (publ) | 14.97 Million SEK | 0.688% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 89.424% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 98.057% |
| CombiGene AB (publ) | 120.61 Million SEK | 87.672% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 93.149% |
| Intervacc AB (publ) | 259.61 Million SEK | 94.273% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 87.447% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | 76.163% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | 64.563% |
| Corline Biomedical AB | 100.1 Million SEK | 85.147% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 91.605% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | 76.076% |
| Aptahem AB (publ) | 63.02 Million SEK | 76.408% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 95.768% |
| Fluicell AB (publ) | 9.34 Million SEK | -59.197% |
| Biovica International AB (publ) | 131.4 Million SEK | 88.685% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | 71.937% |
| Abliva AB (publ) | 87.49 Million SEK | 83.007% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 98.044% |
| 2cureX AB (publ) | 16.62 Million SEK | 10.562% |
| I-Tech AB | 152.44 Million SEK | 90.246% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 98.539% |
| Cyxone AB (publ) | 43.65 Million SEK | 65.94% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 81.105% |
| Biosergen AB | 7.2 Million SEK | -106.485% |
| Nanologica AB (publ) | 77.42 Million SEK | 80.797% |
| SynAct Pharma AB | 228.01 Million SEK | 93.479% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | 44.442% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 98.938% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | 31.488% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 93.762% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -75.86% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 82.923% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | 47.843% |